Publications [#362071] of Charmaine D. Royal

search PubMed.

Essays, Articles, Chapters in Books

  1. Callier, SL; Payne, PW; Akinniyi, D; McPartland, K; Richardson, TL; Rothstein, MA; Royal, CDM, Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing., Journal of racial and ethnic health disparities, vol. 9 no. 6 (December, 2022), pp. 2146-2156 [doi] .
    (last updated on 2024/11/03)

    Abstract:

    Objectives

    We explored cardiologists' attitudes and prescribing patterns specific to the use of generic isosorbide dinitrate and hydralazine hydrochloride, and the fixed-dose patented drug, BiDil.

    Background

    Since the Food and Drug Administration approved BiDil in 2005 with an indication for self-identified black patients, disagreement about the appropriateness of race-based drugs has intensified and led to calls for providers and researchers to abandon race-based delimitations. This paper reports empirical evidence of cardiologists' views on BiDil's race-based indication and their ongoing inertia with respect to the debate about BiDil.

    Methods

    We conducted a 2010 cross-sectional online survey of members of the Association of Black Cardiologists.

    Results

    Fifty-nine cardiologists responded to the survey. Most participants (62.7%) prescribed BiDil to their patients. More than 40% of respondents did not prescribe BiDil to any non-African Americans. When considering whether to prescribe BiDil, a patient's race determined by physician assessment was the third most important factor considered by participants. The majority of participants (72.7%) selected symptoms as the most important factor. Most participants (59.2%) perceived race as defining biologically distinct individuals. Respondents prescribed BiDil more often to African American patients than non-African American patients. However, they prescribed the generic components that makeup BiDil to African Americans and non-African American patients similarly.

    Conclusions

    The survey provides useful findings that, when viewed within the context of ongoing debates about race-based medicine, show little progress toward appropriately utilizing BiDil to maximize health outcomes, yet, might inform the development of practical and effective guidelines concerning the use of race in medicine.